PHOTO ADVISORY -- EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relap

Editors are advised that high-resolution photos are available to accompany the news release, SF07905, EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis, issued earlier today by EMD Serono, Inc.

Caption-a: EMD Serono Logo 1

Caption-b: EMD Serono Logo 2 ... (PRNewsFoto)

Members of the media may download the photos at no charge from the following online archives:

-- PR Newswire Photo Archive: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-a

-- PR Newswire Photo Archive: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-b

For more information on the photos, or on gaining access to the archives, media may contact the PR Newswire Photo Desk at [email protected] .

/PRNewswire -- 11/26/2010/

SOURCE EMD Serono, Inc.

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.